Ongoing challenges of a global international patient assistance program
Ongoing challenges of a global international patient assistance program
复制标题
DOI：
10.1093/annonc/mdl987
复制
发表时间：
2006-01-01
影响因子：
50.5
通讯作者：
Jootar, S.
中科院分区：
文献类型：
--
作者：
Lassarat, S.;Jootar, S.
诺华肿瘤公司支持的Glivec国际患者援助计划（GIPAP（TM））为发展中国家无法负担治疗费用的患者免费提供Glivec（伊马替尼），这是一种治疗慢性粒细胞白血病和胃肠道间质瘤的创新口服疗法。该项目采用一种新的直接面向患者的方法，目前正在81个国家成功地为服务不足的患者提供Glivec。在癌症不是优先事项的国家，以及医疗保健和其他基础设施非常有限的国家，实施这一计划面临着许多挑战。通过在每个国家现有的医疗保健系统内工作，并与任何可能实施的国家癌症控制计划合作，通过仔细选择合格的机构和医生，同时保持全球方法以确保一致性和质量，GIPAP已成为一个有效和可持续的获取计划。诺华对GIPAP做出了长期承诺，目前正在探索其他药物的新患者获取计划。
The Glivec International Patient Assistance Program (GIPAP(TM)) that is supported by Novartis Oncology provides Glivec (imatinib), an innovative oral therapy for chronic myelogenous leukemia and gastrointestinal stromal tumours, at no cost to patients in developing countries who could otherwise not afford treatment. Using a novel direct-to-patient approach this program is currently successfully providing Glivec to underserved patients in 81 countries. A number of challenges were faced in the implementation of this program in countries where cancer is not a priority, and where the healthcare and other infrastructure can be very limited. By working within the existing healthcare system of each country, and with any national cancer control programme that may be in place, through careful selection of qualified institutions and physicians, while maintaining a global approach to ensure consistency and quality, GIPAP has become an efficient and sustainable access program. Novartis has made a long-term commitment to GIPAP, and is currently exploring new patient access programs for other drugs.